The board of ODI Pharma AB (“ODI” or the “Company”) has today appointed Jan-Mark Edewaard as the new CEO of ODI as of January 1, 2025....

Aktieägarna i ODI Pharma AB (publ), 559223–1392, kallas härmed till årsstämma fredagen den 13 december 2024 kl. 10:00 i bolagets lokaler...

The shareholders of ODI Pharma AB (publ), 559223–1392, are hereby invited to attend the Annual General Meeting on Friday, 13th of...

Aktieägarna i ODI Pharma AB (publ), 559223-1392 , kallas härmed till extra bolagsstämma tisdagen den 19 november 2024 kl. 14.30 i...

The shareholders of ODI Pharma AB (publ), 559223-1392 , are hereby invited to an Extraordinary General Meeting to be held on Tuesday 19...

Malcolm Allan is proposed to be elected as a new member of the Board of Directors of ODI Pharma AB at the Extraordinary General Meeting...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA,...

ODI Pharma AB (“ODI” or the “Company”) hereby publishes its year-end report for the period July 2023 – June 2024. The report is available...

ODI Pharma AB (“ODI” or the “Company”) is pleased to announce the first delivery of cannabis products to the leading medical cannabis...

ODI Pharma AB (“ODI” or the “Company”) hereby publishes its interim report for the period July 2023 - March 2024. The report is available...

ODI Pharma AB (“ODI” or the “Company”) announces today that the preliminary financial results for the third quarter of fiscal year...

ODI Pharma AB (“ODI” or the “Company”) hereby present an updated overview of its market position and the latest trends observed in the...

ODI Pharma AB (“ODI” or the “Company”) hereby publishes its half-year report for the period July – December 2023. The report is available...

ODI Pharma AB (”ODI Pharma” eller ”Bolaget”) har idag utsett Pareto Securities till likviditetsgarant för Bolagets aktie som är upptagen...

ODI Pharma AB (“ODI Pharma” or the “Company”) has today appointed Pareto Securities as the liquidity guarantor for the Company's shares,...

This is an unofficial translation of a notice to the Annual General Meeting in ODI Pharma AB (publ), originally drafted in Swedish. In...

Idag den 15 december 2023 hölls årsstämma i ODI Pharma AB (publ). Nedan följer en sammanfattning av de beslut som fattades. Samtliga...

ODI Pharma AB (“ODI” or the “Company”) announces today the sale of the skincare brand kandol. to Niclas Kappelin. The transaction, valued...

The correction refers to the completion of the auditor's remark and ODI Pharma's comment which is now included in the press release. The...

Rättelsen avser komplettering av revisorns anmärkning och ODI Pharmas kommentar som nu finns inkluderat i pressmeddelandet. Bifogad...